Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2114468

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2012

Description:

Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2012', provides an overview of the Transitional Cell Cancer (Urothelial Cell Cancer) therapeutic pipeline. This report provides information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer). 'Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Transitional Cell Cancer (Urothelial Cell Cancer).
- A review of the Transitional Cell Cancer (Urothelial Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Transitional Cell Cancer (Urothelial Cell Cancer).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Transitional Cell Cancer (Urothelial Cell Cancer) pipeline depth and focus of Transitional Cell Cancer (Urothelial Cell Cancer) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutic Products under Development, Key Players in Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Overview, Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline, Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Assessment

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Transitional Cell Cancer (Urothelial Cell Cancer) Overview
Therapeutics Development
An Overview of Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer)
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics under Development by Companies
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics – Products under Development by Companies
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Novartis AG
ImClone Systems Incorporated
AEterna Zentaris Inc.
Allos Therapeutics, Inc
Dendreon Corporation
Debiopharm Group
Altor BioScience Corporation
Transitional Cell Cancer (Urothelial Cell Cancer) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AEZS-108 - Drug Profile
BMS-582664 - Drug Profile
Volasertib - Drug Profile
Folotyn - Drug Profile
BAY 43-9006 - Drug Profile
Camptosar - Drug Profile
Lonafarnib + Gemcitabine - Drug Profile
TKI258 - Drug Profile
Oxaliplatin - Drug Profile
Abraxane - Drug Profile
Docetaxel + Zactima - Drug Profile
Cisplatin + Gemcitabine + Bevacizumab - Drug Profile
Vorinostat - Drug Profile
Fluorouracil + Leucovorin + Gemcitabine + Cisplatin - Drug Profile
Gemcitabine + Doxorubicin + Paclitaxel + Carboplatin + Filgrastim - Drug Profile
Gemcitabine + Cisplatin + Bevacizumab - Drug Profile
BAY43-9006 - Drug Profile
Paclitaxel + Gemcitabine - Drug Profile
Pazopanib Hydrochloride - Drug Profile
VEGF Trap - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
E7389 - Drug Profile
Iressa - Drug Profile
Abraxane + Carboplatin + Gemcitabine - Drug Profile
gemictabine + paclitaxel - Drug Profile
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Sutent - Drug Profile
BCG Vaccine + Iressa - Drug Profile
Gemcitabine + Cisplatin + Sorafenib - Drug Profile
rAd-IFN - Drug Profile
Erbitux + Taxol - Drug Profile
Erbitux - Drug Profile
Survivin-Derived Peptide Vaccine - Drug Profile
Methotrexate + Cisplatin + Citrovorum Factor - Drug Profile
RAD001 - Drug Profile
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile
Pazopanib + Paclitaxel - Drug Profile
Gemcitabine + Oxaliplatin - Drug Profile
Cisplatin + Gemcitabine + Temsirolimus - Drug Profile
Velcade + Gemzar + Adiramycin - Drug Profile
Cisplatin + Gemcitabine + Sunitinib - Drug Profile
SU-011248 - Drug Profile
Carboplatin + Gemcitabine + Vandetanib - Drug Profile
Carboplatin + Gemcitabine - Drug Profile
Gemcitabine + Paclitaxel - Drug Profile
IMC-1121B + Docetaxel - Drug Profile
Carboplatin + Gemcitabine - Drug Profile
Carboplatin + Gemcitabine + Vandetanib - Drug Profile
Cisplatin + Cyclophosphamide + Adriamycin - Drug Profile
Filgrastim + Carboplatin + Gemcitabine + Ifosfamide + Paclitaxel - Drug Profile
Gemcitabine + Cisplatin + Lenalidomide - Drug Profile
Methotrexate + Vinblastine + Cisplatin - Drug Profile
Fluorouracil + Interferon Alpha + Cisplatin - Drug Profile
Panitumumab + Radiotherapy - Drug Profile
Gemcitabine + Cisplatin + Cetuximab - Drug Profile
Sutent - Drug Profile
Sunitinib - Drug Profile
Carboplatin + Methotrexate + Vinblastine - Drug Profile
Cisplatin + Gemcitabine + Lapatinib - Drug Profile
Pazopanib - Drug Profile
Everolimus + Paclitaxel - Drug Profile
Gemcitabine + Cisplatin + Carboplatin - Drug Profile
Gemcitabine + Paclitaxel + Doxorubicin + Pegfilgrastim - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Cisplatin + Gemcitabine + Sorafenib - Drug Profile
Gemcitabine - Drug Profile
Cisplatin + Cyclophosphamide+ Doxorubicin - Drug Profile
Thiotepa - Drug Profile
Gemcitabine Hydrochloride + Doxorubicin + Paclitaxel + Cisplatin + Filgrastim - Drug Profile
Doxorubicin + Gemcitabine + Paclitaxel + Cisplatin + Ifosfamide + Filgrastim - Drug Profile
ABT-888 + Cisplatin + Gemcitabine Hydrochloride - Drug Profile
ALT-801 + Gemcitabine + Cisplatin - Drug Profile
Abraxane - Drug Profile
Gemcitabine + Cisplatin + Lenalidomide - Drug Profile
Gemcitabine + Carboplatin + Lenalidomide - Drug Profile
DN24-02 - Drug Profile
Debio 1141 - Drug Profile
CHP-NY-ESO-1 Cancer Vaccine + MIS416 - Drug Profile
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics – Drug Profile Updates
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics – Discontinued Products
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H1 2012
Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
Boehringer Ingelheim GmbH, H1 2012
Novartis AG, H1 2012
ImClone Systems Incorporated, H1 2012
AEterna Zentaris Inc., H1 2012
Allos Therapeutics, Inc, H1 2012
Dendreon Corporation, H1 2012
Debiopharm Group, H1 2012
Altor BioScience Corporation, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics – Drug Profile Updates
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics – Discontinued Products
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H1 2012
Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Saturday, May 25, 2013
7:09:11 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2012

Web Address

http://www.researchandmarkets.com/reports/2114468

Office Code

OC8DIQSMQRPWWW

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Saturday, May 25, 2013
7:09:11 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2012

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)